Source:http://linkedlifedata.com/resource/pubmed/id/16224397
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2005-10-14
|
pubmed:abstractText |
Excision repair cross-complementation group 1 (ERCC1) is a highly conserved protein and an essential member of the nucleotide excision repair pathway. DNA repair is an important mechanism for resistance to platinum-based chemotherapy. Previous studies have shown that ERCC1 gene expression is associated with clinical outcome to platinum chemotherapy in a variety of cancers. Recently, 2 common polymorphisms in the ERCC1 gene have been described. The first is a single nucleotide polymorphism at codon 188 of the ERCC1 gene that causes a C-->T change but codes for the same amino acid, asparagine. This polymorphism may be associated with differential ERCC1 gene expression. The second is also a signal nucleotide polymorphism in the 3'-untranslated region and may affect MRNA stability. We hypothesized that these 2 polymorphisms may be associated with clinical outcome to platinum-based chemotherapy. We assessed the relationship between these ERCC1 gene polymorphism and clinical outcome to platinum-based chemotherapy in 106 patients with advanced refractory colorectal cancer. We found a significant associated between the ERCC1 codon 118 polymorphism and clinical outcome. Patients with the C/C genotype had a median survival of 15.3 months (95% CI, 6.0-12.1) and 11.1 months (95% CI, 5.8-16.2) for those with C/T and T/T genotypes, respectively. The ERCC1 codon 118 polymorphism may be a useful predictor of clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/ERCC1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Endonucleases,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1543-0790
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
162-6
|
pubmed:meshHeading |
pubmed-meshheading:16224397-Adult,
pubmed-meshheading:16224397-Aged,
pubmed-meshheading:16224397-Aged, 80 and over,
pubmed-meshheading:16224397-Colorectal Neoplasms,
pubmed-meshheading:16224397-DNA-Binding Proteins,
pubmed-meshheading:16224397-Endonucleases,
pubmed-meshheading:16224397-Female,
pubmed-meshheading:16224397-Fluorouracil,
pubmed-meshheading:16224397-Genotype,
pubmed-meshheading:16224397-Humans,
pubmed-meshheading:16224397-Male,
pubmed-meshheading:16224397-Middle Aged,
pubmed-meshheading:16224397-Organoplatinum Compounds,
pubmed-meshheading:16224397-Polymorphism, Single Nucleotide,
pubmed-meshheading:16224397-Predictive Value of Tests,
pubmed-meshheading:16224397-Prognosis,
pubmed-meshheading:16224397-Retrospective Studies,
pubmed-meshheading:16224397-Survival Analysis
|
pubmed:year |
2003
|
pubmed:articleTitle |
ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
|
pubmed:affiliation |
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles 90033, USA.
|
pubmed:publicationType |
Journal Article
|